Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX53 First-in-Human Study in Advanced Solid Tumors
NCT05394168Phase 1Active, not recruiting
- Sponsor
- Henlius
- Start
- Dec 2022
- Primary completion
- Dec 2024
- Modality
- Antibody Conjugates, Engineered Antibody Formats, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HLX53 in solid tumor, sponsored by Henlius. Primary endpoints: Adverse event, Incidence of Dose-Limiting Toxicity up to 3 weeks and 2 more. Started Dec 2022; status: active, not recruiting.
02
Drugs
HLX53
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05394168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05394168.